1. Home
  2. IMUX vs APLT Comparison

IMUX vs APLT Comparison

Compare IMUX & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMUX
  • APLT
  • Stock Information
  • Founded
  • IMUX 2016
  • APLT 2016
  • Country
  • IMUX United States
  • APLT United States
  • Employees
  • IMUX N/A
  • APLT N/A
  • Industry
  • IMUX Biotechnology: Pharmaceutical Preparations
  • APLT Biotechnology: Pharmaceutical Preparations
  • Sector
  • IMUX Health Care
  • APLT Health Care
  • Exchange
  • IMUX Nasdaq
  • APLT Nasdaq
  • Market Cap
  • IMUX 86.3M
  • APLT 80.3M
  • IPO Year
  • IMUX N/A
  • APLT 2019
  • Fundamental
  • Price
  • IMUX $1.00
  • APLT $0.65
  • Analyst Decision
  • IMUX Strong Buy
  • APLT Buy
  • Analyst Count
  • IMUX 6
  • APLT 7
  • Target Price
  • IMUX $12.67
  • APLT $6.10
  • AVG Volume (30 Days)
  • IMUX 923.9K
  • APLT 3.5M
  • Earning Date
  • IMUX 02-24-2025
  • APLT 03-05-2025
  • Dividend Yield
  • IMUX N/A
  • APLT N/A
  • EPS Growth
  • IMUX N/A
  • APLT N/A
  • EPS
  • IMUX N/A
  • APLT N/A
  • Revenue
  • IMUX N/A
  • APLT N/A
  • Revenue This Year
  • IMUX N/A
  • APLT N/A
  • Revenue Next Year
  • IMUX N/A
  • APLT $2,622.90
  • P/E Ratio
  • IMUX N/A
  • APLT N/A
  • Revenue Growth
  • IMUX N/A
  • APLT N/A
  • 52 Week Low
  • IMUX $0.92
  • APLT $0.54
  • 52 Week High
  • IMUX $2.11
  • APLT $10.62
  • Technical
  • Relative Strength Index (RSI)
  • IMUX 50.39
  • APLT 35.67
  • Support Level
  • IMUX $0.92
  • APLT $0.54
  • Resistance Level
  • IMUX $0.97
  • APLT $0.66
  • Average True Range (ATR)
  • IMUX 0.06
  • APLT 0.06
  • MACD
  • IMUX 0.01
  • APLT 0.09
  • Stochastic Oscillator
  • IMUX 66.61
  • APLT 81.26

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.

About APLT Applied Therapeutics Inc.

Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.

Share on Social Networks: